3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Gastrointestinal
1
Dermatologic
1
Conditions
Pathologic Complete Response
1
Leukemia, Myeloid, Acute
1
Interventions
venetoclax
308
Cyclophosphamide
231
Cytarabine
201
Azacitidine
191
fludarabine
181
Specimen Handling
136
Biopsy
103
fludarabine phosphate
97
Methotrexate
82
Rituximab
79
Daunorubicin
77
Dexamethasone
76
Vincristine
69
Whole-Body Irradiation
64
Mycophenolic Acid
59
Decitabine
58
Tacrolimus
55
Etoposide
53
ibrutinib
52
blinatumomab
51
Granulocyte Colony-Stimulating Factor
51
obinutuzumab
50
Busulfan
50
Prednisone
49
Melphalan
48
acalabrutinib
46
Injections
46
Stem Cell Transplantation
45
Idarubicin
45
Magnetic Resonance Spectroscopy
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Monatide (IMS 3015)
×
Other hematologic neoplasm
×
1 year
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled